Legal & General Group Plc Has $382.34 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Legal & General Group Plc boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 961,496 shares of the biopharmaceutical company’s stock after buying an additional 73,716 shares during the period. Legal & General Group Plc’s holdings in Alnylam Pharmaceuticals were worth $382,339,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $29,000. Ameriflex Group Inc. acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $32,000. Aster Capital Management DIFC Ltd acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $36,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $39,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on ALNY. Royal Bank Of Canada reduced their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total value of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares in the company, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 21,255 shares of company stock worth $6,930,337 in the last quarter. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.7%

ALNY opened at $295.50 on Wednesday. The company’s 50 day moving average is $310.41 and its 200-day moving average is $357.09. Alnylam Pharmaceuticals, Inc. has a 1-year low of $284.28 and a 1-year high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company has a market cap of $39.45 billion, a P/E ratio of 80.74 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the company posted ($0.44) EPS. The firm’s quarterly revenue was up 96.4% compared to the same quarter last year. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.